查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1886617

青光眼治療市場－全球產業規模、佔有率、趨勢、機會和預測，依治療類型、青光眼類型、地區和競爭格局分類，2020-2030年預測

Glaucoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Glaucoma Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球青光眼治療市場規模為73.3億美元，預計2030年將以6.57%的複合年成長率成長至107.4億美元。全球青光眼治療市場涵蓋旨在降低眼內壓和預防視神經損傷的藥物和手術干預措施，從而保護青光眼患者的視力。推動市場成長的關鍵因素包括全球青光眼盛行率的上升和老年人口的不斷成長。

市場概覽
預測期 2026-2030
市場規模：2024年 73.3億美元
市場規模：2030年 107.4億美元
複合年成長率：2025-2030年 6.57%
成長最快的細分市場 藥物
最大的市場 北美洲

主要市場促進因素

全球老年人口的成長代表著人口結構的根本轉變，對青光眼治療市場產生了顯著影響。隨著年齡的成長，個體患青光眼的風險顯著增加，因此，人口老化是推動患者數量成長的主要因素。

主要市場挑戰

患者長期用藥依從性差是全球青光眼治療市場擴張的一大障礙。青光眼藥物治療的療效從根本上取決於患者能否持續、及時地堅持用藥，從而有效降低眼壓，並防止視神經損傷加重。

主要市場趨勢

將人工智慧應用於青光眼診斷和治療代表著一種變革性趨勢，它提高了患者護理的精確度和效率。人工智慧演算法可以分析複雜的眼科影像和臨床資料，從而促進疾病的早期發現和更準確的病情進展監測，進而實現及時介入。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球青光眼治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療類型（眼藥水、藥物、雷射手術、傳統手術）
    • 依青光眼類型（開角型、閉角型）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美青光眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲青光眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區青光眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲青光眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲青光眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球青光眼治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Novartis AG
  • Merck & Co., Inc.
  • AbbVie, Inc.
  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Alcon, Inc.
  • Inotek Pharmaceuticals Corporation

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22729

The Global Glaucoma Therapeutics Market , valued at USD 7.33 Billion in 2024, is projected to experience a CAGR of 6.57% to reach USD 10.74 Billion by 2030. The global glaucoma therapeutics market encompasses pharmacological and surgical interventions designed to reduce intraocular pressure and prevent optic nerve damage, thereby preserving vision in individuals diagnosed with glaucoma. Key drivers supporting market growth include the rising global prevalence of glaucoma and the expanding geriatric population.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.33 Billion
Market Size 2030USD 10.74 Billion
CAGR 2025-20306.57%
Fastest Growing SegmentMedication
Largest MarketNorth America

Key Market Drivers

The increasing global geriatric population represents a fundamental demographic shift significantly influencing the glaucoma therapeutics market. As individuals age, their susceptibility to developing glaucoma rises substantially, making this demographic expansion a primary driver of increased patient volumes. Older age is a well-established risk factor for glaucoma onset and progression, directly translating to a greater need for diagnostic screenings and subsequent therapeutic interventions.

Key Market Challenges

Patient non-adherence to long-term medication regimens presents a substantial impediment to the expansion of the global glaucoma therapeutics market. The efficacy of pharmacological interventions for glaucoma is fundamentally dependent on consistent and timely patient compliance to effectively reduce intraocular pressure and avert progressive optic nerve damage. When individuals do not adhere to their prescribed treatment schedules, the disease often progresses unchecked, leading to a greater need for more advanced and often expensive surgical procedures or a shift to alternative, more complex drug therapies. This undermines the overall perceived value and effectiveness of current pharmaceutical offerings and disrupts the consistent demand for long-term medication supplies.

Key Market Trends

The integration of artificial intelligence in glaucoma diagnostics and management represents a transformative trend, enhancing the precision and efficiency of patient care. AI algorithms can analyze complex ophthalmic imaging and clinical data to facilitate earlier disease detection and more accurate progression monitoring, thereby enabling timely interventions.

Key Market Players

  • Novartis AG
  • Merck & Co., Inc.
  • AbbVie, Inc.
  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Alcon, Inc.
  • Inotek Pharmaceuticals Corporation

Report Scope:

In this report, the Global Glaucoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glaucoma Therapeutics Market , By Treatment Type:

  • Eye drops
  • Medication
  • Laser Surgery
  • Traditional Surgery

Glaucoma Therapeutics Market , By Glaucoma Type:

  • Open angle
  • Closed angle

Glaucoma Therapeutics Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Glaucoma Therapeutics Market .

Available Customizations:

Global Glaucoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glaucoma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Eye drops, Medication, Laser Surgery, Traditional Surgery)
    • 5.2.2. By Glaucoma Type (Open angle, Closed angle)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Glaucoma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Glaucoma Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Glaucoma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Glaucoma Type
    • 6.3.2. Canada Glaucoma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Glaucoma Type
    • 6.3.3. Mexico Glaucoma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Glaucoma Type

7. Europe Glaucoma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Glaucoma Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Glaucoma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Glaucoma Type
    • 7.3.2. France Glaucoma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Glaucoma Type
    • 7.3.3. United Kingdom Glaucoma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Glaucoma Type
    • 7.3.4. Italy Glaucoma Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Glaucoma Type
    • 7.3.5. Spain Glaucoma Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Glaucoma Type

8. Asia Pacific Glaucoma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Glaucoma Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Glaucoma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Glaucoma Type
    • 8.3.2. India Glaucoma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Glaucoma Type
    • 8.3.3. Japan Glaucoma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Glaucoma Type
    • 8.3.4. South Korea Glaucoma Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Glaucoma Type
    • 8.3.5. Australia Glaucoma Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Glaucoma Type

9. Middle East & Africa Glaucoma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Glaucoma Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Glaucoma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Glaucoma Type
    • 9.3.2. UAE Glaucoma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Glaucoma Type
    • 9.3.3. South Africa Glaucoma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Glaucoma Type

10. South America Glaucoma Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Glaucoma Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Glaucoma Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Glaucoma Type
    • 10.3.2. Colombia Glaucoma Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Glaucoma Type
    • 10.3.3. Argentina Glaucoma Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Glaucoma Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Glaucoma Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. AbbVie, Inc.
  • 15.4. Bausch Health Companies, Inc.
  • 15.5. Teva Pharmaceutical Industries Ltd.
  • 15.6. Pfizer Inc.
  • 15.7. Alcon, Inc.
  • 15.8. Inotek Pharmaceuticals Corporation

16. Strategic Recommendations

17. About Us & Disclaimer